Pharmaceuticals

Endometrial Cancer Treatment Market Outlook: Growth and Forecast Highlights 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the endometrial cancer treatment market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Endometrial Cancer Treatment Market covering 2026–2035?

The endometrial cancer treatment market has demonstrated significant expansion in recent years. It is projected to increase from $32.09 billion in 2025 to $33.85 billion in 2026, at a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to a rising incidence of endometrial cancer, limited early diagnostic tools, a preference for conventional chemotherapy, a lack of targeted therapies, and low awareness about preventive care.

The endometrial cancer treatment market is expected to witness robust expansion over the next few years. It is forecast to grow to $43.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. The increase during this forecast period can be attributed to advancements in genomics and precision medicine, the rising adoption of AI-driven diagnostics, the growth of targeted and immunotherapy drugs, an aging global population, and improvements in healthcare infrastructure. Prominent trends for the forecast period include individualized treatment plans, minimally invasive surgical procedures, the ongoing development of targeted therapies, combination therapy approaches, and enhanced patient monitoring and follow-up care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10735&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Endometrial Cancer Treatment Market?

The increasing occurrence of endometrial cancer is anticipated to propel the expansion of the endometrial cancer treatment market in the future. The prevalence of endometrial cancer signifies a rise in the number of diagnosed cases within a given population or over a specific period. This trend is a result of evolving risk factors, improved detection and diagnostic methods, heightened awareness, and an aging population. Endometrial cancer treatments play a vital role in early detection, offering targeted therapies, preventing recurrence, and advancing options through clinical trials and research studies. As the incidence of endometrial cancer continues its upward trajectory and therapeutic innovations broaden, the endometrial cancer treatment market is expected to grow. For instance, in 2023, Cancer.Net, an oncologist-approved cancer information website, estimated that 66,200 people in the United States would be diagnosed with uterine, or endometrial cancer. Consequently, the rising prevalence of endometrial cancer is a key driver for the growth of the endometrial cancer treatment market.

What Segments Are Identified Within The Structure Of The Endometrial Cancer Treatment Market?

The endometrial cancer treatment market covered in this report is segmented –

1) By Type: Adenocarcinoma, Uterine Carcinosarcoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Transitional Carcinoma, Serous Carcinoma, Other Types

2) By Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, Other Diagnosis Methods

3) By Route Of Administration: Oral, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Adenocarcinoma: Endometrioid Adenocarcinoma, Non-Endometrioid Adenocarcinoma

2) By Uterine Carcinosarcoma: High-Grade Uterine Carcinosarcoma, Low-Grade Uterine Carcinosarcoma

3) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma

4) By Small Cell Carcinoma: Small Cell Neuroendocrine Carcinoma

5) By Transitional Carcinoma: Transitional Cell Carcinoma Of The Uterus

6) By Serous Carcinoma: High-Grade Serous Carcinoma, Low-Grade Serous Carcinoma

7) By Other Types: Mixed Cell Type Carcinomas, Undifferentiated Carcinoma, Other Rare Histological Types

What Trends Are Expected To Impact The Competitive Landscape Of The Endometrial Cancer Treatment Market?

Major companies in the endometrial cancer treatment market are prioritizing the development of advanced solutions, such as PD-1 pathway blocking immunotherapy, to boost treatment effectiveness and the durability of patient responses. This immunotherapy operates by preventing cancer cells from utilizing the PD-1 mechanism to evade immune detection, thereby enabling immune cells to identify and attack tumors with greater precision. This method provides a targeted solution for advanced or recurrent disease where traditional chemotherapy has often offered limited long-term benefits. For instance, in August 2025, GSK Plc, a UK-based biopharma company, launched Jemperli, which incorporates a PD-1 blocking mechanism. This therapy is India’s first approved immunotherapy for the second-line treatment of mismatch repair deficient or microsatellite instability high advanced endometrial cancer, having demonstrated an objective response rate of 45.5 percent in the GARNET trial. It maintains strong probabilities of sustained response at 12 and 24 months and offers an acceptable safety profile. This launch addresses a critical unmet need in India, where a significant number of patients present with advanced disease and require more effective and predictable treatment options.

Which Major Industry Participants Are Leading The Endometrial Cancer Treatment Market Growth?

Major companies operating in the endometrial cancer treatment market are Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi-Aventis, Teva Pharmaceutical Industries Limited, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., AbbVie Inc., Roche Holding AG, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eli Lilly and Company, Varian Medical Systems Inc., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Stemline Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Endometrial Cancer Treatment Market?

North America was the largest region in the endometrial cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global endometrial cancer treatment market report during the forecast period. The regions covered in the endometrial cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Endometrial Cancer Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10735&type=smp

Browse Through More Reports Similar to the Global Endometrial Cancer Treatment Market 2026, By The Business Research Company

Endometrial Cancer Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report

Endometriosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

Gynecological Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gynecological-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795